These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10877056)

  • 1. Pentostatin (Nipent) and high-dose cyclophosphamide for the treatment of refractory autoimmune disorders.
    Goodman M
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):67-71. PubMed ID: 10877056
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activity of pentostatin (Nipent) in cutaneous T-cell lymphoma: single-agent and combination studies.
    Foss FM
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):58-63. PubMed ID: 10877054
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trials of pentostatin (Nipent) in hairy cell leukemia.
    Kraut EH
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):27-31. PubMed ID: 10877048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
    Dearden CE; Matutes E; Catovsky D
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):22-6. PubMed ID: 10877047
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pentostatin (Nipent) in the treatment of chronic lymphocyte leukemia and hairy cell leukemia.
    Dillman RO
    Expert Rev Anticancer Ther; 2004 Feb; 4(1):27-36. PubMed ID: 14748654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pentostatin (Nipent): a review of potential toxicity and its management.
    Margolis J; Grever MR
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):9-14. PubMed ID: 10877045
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Future directions for pentostatin (Nipent) usage in dermatology.
    Heald P
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):3-8. PubMed ID: 10877044
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An old drug for a new disease: pentostatin (Nipent) in acute graft-versus-host disease.
    Margolis J; Vogelsang G
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):72-7. PubMed ID: 10877057
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentostatin (Nipent) in T-cell lymphomas.
    Kurzrock R
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):64-6. PubMed ID: 10877055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Deoxycoformycin (pentostatin): clinical pharmacology, role in the chemotherapy of cancer, and use in other diseases.
    Spiers AS
    Haematologia (Budap); 1996; 27(2):55-84. PubMed ID: 14651224
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-dose cyclophosphamide therapy without stem cell rescue for severe refractory autoimmune illnesses: comment on the article by Moore et al.
    Prestrud AA; Hoch S; Brodsky I; Gladstone DE
    Arthritis Rheum; 2003 May; 48(5):1463; author reply 1464-6. PubMed ID: 12746926
    [No Abstract]   [Full Text] [Related]  

  • 12. Nonmyeloablative approaches to the treatment of sickle hemoglobinopathies.
    Amado RG; Schiller GJ
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):82-9. PubMed ID: 10877059
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pentostatin in steroid-refractory acute graft-versus-host disease.
    Bolaños-Meade J; Jacobsohn DA; Margolis J; Ogden A; Wientjes MG; Byrd JC; Lucas DM; Anders V; Phelps M; Grever MR; Vogelsang GB
    J Clin Oncol; 2005 Apr; 23(12):2661-8. PubMed ID: 15837980
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Future development of pentostatin (Nipent): opportunities for using a highly effective, safe agent for hematologic and autoimmune diseases. Proceedings of a conference. Puerto Rico, February 12-13, 1999.
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):1-105. PubMed ID: 10877043
    [No Abstract]   [Full Text] [Related]  

  • 15. High-dose cyclophosphamide without stem cell transplantation in systemic lupus erythematosus.
    Petri M; Jones RJ; Brodsky RA
    Arthritis Rheum; 2003 Jan; 48(1):166-73. PubMed ID: 12528116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Theophylline, pentostatin (Nipent), and chlorambucil: a dose-escalation study targeting intrinsic biologic resistance mechanisms in patients with relapsed lymphoproliferative disorders.
    Byrd JC; Grever MR; Waselenko JK; Willis CR; Park K; Goodrich A; Lucas MA; Shinn C; Flinn IW
    Semin Oncol; 2000 Apr; 27(2 Suppl 5):37-40. PubMed ID: 10877050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pentostatin for the treatment of indolent lymphoproliferative disorders.
    Ho AD; Hensel M
    Semin Hematol; 2006 Apr; 43(2 Suppl 2):S2-10. PubMed ID: 16549110
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High-dose lymphoablative therapy (HDLT) with or without autologous stem-cell rescue for treatment of severe autoimmune diseases.
    Tecnologica MAP Suppl; 2001 Dec; ():29-9. PubMed ID: 11933938
    [No Abstract]   [Full Text] [Related]  

  • 19. High-dose chemotherapy and autologous hematopoietic stem cell transplantation in patients with rheumatoid arthritis: results of an open study to assess feasibility, safety, and efficacy.
    Verburg RJ; Kruize AA; van den Hoogen FH; Fibbe WE; Petersen EJ; Preijers F; Sont JK; Barge RM; Bijlsma JW; van de Putte LB; Breedveld FC; van Laar JM
    Arthritis Rheum; 2001 Apr; 44(4):754-60. PubMed ID: 11315914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pentostatin and purine analogs for indolent lymphoid malignancies.
    Ho AD; Hensel M
    Future Oncol; 2006 Apr; 2(2):169-83. PubMed ID: 16563086
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.